Seeking Alpha

Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales...

Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales in the six weeks after November 21, slaying a Q4 anlayst forecast of $5M. Regeneron also predicted that 2012 revenue from the medicine would reach $140M-160M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs